You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBuspirone
Accession NumberDB00490  (APRD00222)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to diazepam. [PubChem]
Structure
Thumb
Synonyms
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
Buspiron
Buspirona
Buspirone
Buspironum
External Identifiers
  • MJ 90221-1
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Buspar Tab 10mgtablet10 mgoralBristol Myers Squibb Canada1989-12-312010-11-12Canada
Buspironetablet10 mgoralSanis Health Inc2016-02-17Not applicableCanada
Buspirone-10 - Tab 10mgtablet10 mgoralPro Doc Limitee1997-01-15Not applicableCanada
Bustabtablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Bustabtablet5 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Co Buspironetablet10 mgoralCobalt Pharmaceuticals Company2005-11-092012-08-02Canada
Dom-buspironetablet10 mgoralDominion Pharmacal1999-10-25Not applicableCanada
Ftp-buspironetablet10 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Linbuspironetablet10 mgoralLinson Pharma Co.1996-12-312006-05-29Canada
Mylan-buspironetablet10 mgoralMylan Pharmaceuticals Ulc1997-03-132010-08-04Canada
Nu-buspirone - Tab 10mgtablet10 mgoralNu Pharm Inc1996-12-312012-09-04Canada
Penta-buspironetablet10 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PMS-buspironetablet5 mgoralPharmascience Inc1997-06-05Not applicableCanada
PMS-buspironetablet10 mgoralPharmascience Inc1997-05-26Not applicableCanada
Ratio-buspironetablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1998-06-102010-05-17Canada
Riva-buspirone 10 mgtablet10 mgoralLaboratoire Riva Inc2003-03-03Not applicableCanada
Teva-buspironetablet10 mgoralTeva Canada Limited1997-09-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-buspirone - Tab 10mgtablet10 mgoralApotex Inc1996-12-31Not applicableCanada
Buspironetablet10 mg/1oralSTAT Rx USA LLC2002-03-01Not applicableUs
Buspirone HCltablet5 mg/1oralTYA Pharmaceuticals2001-03-28Not applicableUs
Buspirone HCltablet5 mg/1oralClinical Solutions Wholesale2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralbryant ranch prepack2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HCltablet15 mg/1oralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HCltablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralTYA Pharmaceuticals2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Buspirone HCltablet10 mg/1oralMedsource Pharmaceuticals2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralCardinal Health2001-03-28Not applicableUs
Buspirone HCltablet5 mg/1oralbryant ranch prepack2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralDispensing Solutions, Inc.2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HCltablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Buspirone HCltablet10 mg/1oralProficient Rx LP2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HCltablet5 mg/1oralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralUnit Dose Services2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralDispensing Solutions, Inc.2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Buspirone HCltablet5 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-24Not applicableUs
Buspirone HCltablet5 mg/1oralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HCltablet10 mg/1oralWatson Laboratories, Inc.2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralSTAT Rx USA LLC2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralRebel Distributors Corp.2001-03-28Not applicableUs
Buspirone HCltablet15 mg/1oralProficient Rx LP2001-03-28Not applicableUs
Buspirone HCltablet5 mg/1oralAmerican Health Packaging2013-05-282015-12-29Us
Buspirone HCltablet10 mg/1oralClinical Solutions Wholesale2001-03-28Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2015-01-12Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralMajor Pharmaceuticals2009-08-09Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-03-21Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-25Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralMylan Pharmaceuticals Inc.2001-03-28Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralCardinal Health2001-03-28Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralCarilion Materials Management2002-02-28Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-06-01Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralAidarex Pharmaceuticals LLC2002-03-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralPar Pharmaceutical Inc.2012-04-23Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralTeva Pharmaceuticals USA Inc2002-02-28Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2011-03-23Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2010-12-15Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralH.J. Harkins Company, Inc.2010-12-23Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-07-08Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralRebel Distributors Corp2009-09-09Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralMylan Institutional Inc.2002-03-25Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralMylan Pharmaceuticals Inc.2002-03-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2015-01-12Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralPreferred Pharmaceuticals Inc.2015-10-08Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2013-05-03Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralMylan Pharmaceuticals Inc.2001-06-28Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralClinical Solutions Wholesale, Llc2014-05-03Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralRebel Distributors Corp2010-12-23Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralTeva Pharmaceuticals USA Inc2002-02-28Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralMc Kesson Contract Packaging2011-11-07Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralSTAT Rx USA LLC2010-07-01Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2011-08-23Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2010-12-15Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2001-03-28Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-04-23Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralAphena Pharma Solutions Tennessee, Llc2001-03-28Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralMylan Institutional Inc.2002-03-25Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralMylan Pharmaceuticals Inc.2013-07-08Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2015-03-07Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralPreferred Pharmaceuticals Inc.2015-08-19Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralSTAT Rx USA LLC2011-10-05Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralREMEDYREPACK INC.2010-12-07Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2013-05-02Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralCardinal Health2010-03-31Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralPhysicians Total Care, Inc.2012-04-30Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralbryant ranch prepack2010-12-23Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralAv Kare, Inc.2013-08-28Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralTeva Pharmaceuticals USA Inc2002-03-01Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralProficient Rx LP2002-03-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralMc Kesson Contract Packaging2011-11-21Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2011-10-13Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2010-12-15Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralClinical Solutions Wholesale, Llc2014-05-03Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralREMEDYREPACK INC.2014-12-10Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-02-28Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-03-21Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralMylan Institutional Inc.2002-12-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralMylan Pharmaceuticals Inc.2002-03-01Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2015-06-22Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralCardinal Health2010-03-31Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralCadila Healthcare Limited2014-05-03Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralREMEDYREPACK INC.2011-05-12Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralAv Kare, Inc.2013-10-17Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralMylan Institutional Inc.2001-04-15Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralTeva Pharmaceuticals USA Inc2004-03-26Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralDr. Reddy's Laboratories Ltd2009-03-04Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralGolden State Medical Supply, Inc.2015-02-09Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralStrides Arcolab Limited2014-09-05Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-03Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-23Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralbryant ranch prepack2002-03-01Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralCarilion Materials Management2002-02-28Not applicableUs
Buspirone Hydrochloridetablet7.5 mg/1oralAccord Healthcare Inc.2015-09-15Not applicableUs
Buspirone Hydrochloridetablet30 mg/1oralREMEDYREPACK INC.2012-03-29Not applicableUs
Buspirone Hydrochloridetablet10 mg/1oralAidarex Pharmaceuticals LLC2002-02-28Not applicableUs
Buspirone Hydrochloridetablet5 mg/1oralPhysicians Total Care, Inc.2004-12-21Not applicableUs
Buspirone Hydrochloridetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnsialRontag
AnxironValeant
AnxutEisai
BesparNot Available
BuscalmWockhardt
BuspHexal
BusparBristol-Myers Squibb
BusponDeva
DalpasBiotech
EpsilatCoup
PasrinAspen Pharmacare
SpamilanAnpharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Buspirone Hydrochloride
33386-08-2
Thumb
  • InChI Key: RICLFGYGYQXUFH-UHFFFAOYSA-N
  • Monoisotopic Mass: 421.224453
  • Average Mass: 421.964
DBSALT000313
Categories
UNIITK65WKS8HL
CAS number36505-84-7
WeightAverage: 385.5031
Monoisotopic: 385.247775261
Chemical FormulaC21H31N5O2
InChI KeyInChIKey=QWCRAEMEVRGPNT-UHFFFAOYSA-N
InChI
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
IUPAC Name
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
SMILES
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Azaspirodecanedione
  • Azaspirodecane
  • Dialkylarylamine
  • Piperidinedione
  • N-alkylpiperazine
  • Piperidinone
  • Dicarboximide
  • Delta-lactam
  • Pyrimidine
  • Piperidine
  • Carboxylic acid imide, n-substituted
  • Heteroaromatic compound
  • Carboxylic acid imide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.
PharmacodynamicsBuspirone is used in the treatment of generalized anxiety where it has advantages over other antianxiety drugs because it does not cause sedation (drowsiness) and does not cause tolerance or physical dependence. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. in vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo when tested in preclinical models. Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.
Mechanism of actionBuspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced.
Related Articles
AbsorptionRapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.
Volume of distributionNot Available
Protein binding95% (approximately 70% bound to albumin, 30% bound to alpha 1 -acid glycoprotein)
Metabolism

Metabolized hepatically, primarily by oxidation by cytochrome P450 3A4 producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP)

SubstrateEnzymesProduct
Buspirone
1-PyrimidinylpiperazineDetails
Buspirone
Buspirone N-oxideDetails
Buspirone
3′-HydroxybuspironeDetails
Buspirone
5-HydroxybuspironeDetails
Buspirone
6'-HydroxybuspironeDetails
Route of eliminationIn a single-dose study using 14C-labeled buspirone, 29% to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites; fecal excretion accounted for 18% to 38% of the dose.
Half life2-3 hours (although the action of a single dose is much longer than the short halflife indicates).
ClearanceNot Available
ToxicityOral, rat LD50 = 136 mg/kg. Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier+0.9839
Caco-2 permeable-0.538
P-glycoprotein substrateSubstrate0.5726
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8282
Renal organic cation transporterInhibitor0.598
CYP450 2C9 substrateNon-substrate0.8703
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6728
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.7186
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.6277
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.987
Rat acute toxicity2.8167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7042
hERG inhibition (predictor II)Inhibitor0.6914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb co pharmaceutical research institute
  • Actavis totowa llc
  • Apotex inc
  • Dr reddys laboratories ltd
  • Egis pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral30 mg/1
Tabletoral5 mg/1
Tabletoral7.5 mg/1
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Wellbutrin xl 300 mg tablet8.68USD tablet
Wellbutrin xl 150 mg tablet6.58USD tablet
Buspar 30 mg tablet5.52USD tablet
Buspirone hcl powder4.74USD g
Buspirone hcl 30 mg tablet3.71USD tablet
Buspar 15 mg tablet3.07USD tablet
Buspirone hcl 15 mg tablet2.16USD tablet
Buspar 10 mg tablet2.05USD tablet
Buspirone hcl 7.5 mg tablet1.62USD tablet
Buspirone hcl 10 mg tablet1.42USD tablet
Buspar 5 mg tablet1.18USD tablet
Vanspar 7.5 mg tablet1.18USD tablet
Buspar 10 mg Tablet1.12USD tablet
Buspirone hcl 5 mg tablet0.79USD tablet
Apo-Buspirone 10 mg Tablet0.62USD tablet
Novo-Buspirone 10 mg Tablet0.62USD tablet
Nu-Buspirone 10 mg Tablet0.62USD tablet
Pms-Buspirone 10 mg Tablet0.62USD tablet
Ratio-Buspirone 10 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point201.5-202.5 °CNot Available
water solubility21.4 mg/LNot Available
logP2.63TAKACS-NOVAK,K 1995 (IN PRESS)
Predicted Properties
PropertyValueSource
Water Solubility0.588 mg/mLALOGPS
logP1.95ALOGPS
logP1.78ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area69.64 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity108.89 m3·mol-1ChemAxon
Polarizability44.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-004i-6940000000-197b8ea9ac79cbda753bView in MoNA
References
Synthesis Reference

DrugSyn.org

US3717634
General ReferencesNot Available
External Links
ATC CodesN05BE01
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelDownload (275 KB)
MSDSDownload (75.6 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Buspirone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Buspirone can be decreased when combined with 2-mercaptobenzothiazole.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Buspirone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Buspirone can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Buspirone.
AcepromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Buspirone.
AcetophenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Buspirone.
adipiplonThe risk or severity of adverse effects can be increased when Buspirone is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Buspirone.
AgomelatineThe risk or severity of adverse effects can be increased when Buspirone is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Buspirone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Buspirone.
AlmotriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Almotriptan.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Buspirone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buspirone.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Buspirone.
AmiodaroneThe metabolism of Buspirone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Buspirone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buspirone.
AmobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Amobarbital.
AmorolfineThe metabolism of Buspirone can be decreased when combined with Amorolfine.
AmoxapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amperozide.
Amphotericin BThe metabolism of Buspirone can be decreased when combined with Amphotericin B.
AN2690The metabolism of Buspirone can be decreased when combined with AN2690.
AnidulafunginThe metabolism of Buspirone can be decreased when combined with Anidulafungin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Buspirone.
AprepitantThe serum concentration of Buspirone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Buspirone.
ArtemetherThe metabolism of Buspirone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Asenapine.
AtazanavirThe metabolism of Buspirone can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Buspirone.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Buspirone.
AtomoxetineThe metabolism of Buspirone can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Buspirone.
AzaperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Azaperone.
AzelastineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Buspirone.
BaclofenThe risk or severity of adverse effects can be increased when Buspirone is combined with Baclofen.
Bafilomycin A1The metabolism of Buspirone can be decreased when combined with Bafilomycin A1.
BarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.
BenmoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Benmoxin.
BenzocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzocaine.
Benzoic AcidThe metabolism of Buspirone can be decreased when combined with Benzoic Acid.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Buspirone.
BetaxololThe metabolism of Buspirone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Buspirone can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Buspirone is combined with Bifeprunox.
BifonazoleThe metabolism of Buspirone can be decreased when combined with Bifonazole.
BoceprevirThe metabolism of Buspirone can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Buspirone.
BortezomibThe metabolism of Buspirone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Buspirone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Buspirone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
BrimonidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Buspirone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Buspirone.
BrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buspirone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Buprenorphine.
BupropionThe metabolism of Buspirone can be decreased when combined with Bupropion.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone.
ButacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Buspirone is combined with Butamben.
ButenafineThe metabolism of Buspirone can be decreased when combined with Butenafine.
ButethalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butethal.
ButoconazoleThe metabolism of Buspirone can be decreased when combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Buspirone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Buspirone.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Buspirone.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Buspirone.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Buspirone.
CandicidinThe metabolism of Buspirone can be decreased when combined with Candicidin.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Buspirone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Buspirone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Buspirone.
CariprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Caroxazone.
CaspofunginThe metabolism of Buspirone can be decreased when combined with Caspofungin.
CelecoxibThe metabolism of Buspirone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Buspirone can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Buspirone.
CeruleninThe metabolism of Buspirone can be decreased when combined with Cerulenin.
CetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Buspirone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloroprocaine.
ChloroquineThe metabolism of Buspirone can be decreased when combined with Chloroquine.
ChloroxineThe metabolism of Buspirone can be decreased when combined with Chloroxine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Buspirone can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Buspirone can be decreased when combined with Cholecalciferol.
CiclopiroxThe metabolism of Buspirone can be decreased when combined with Ciclopirox.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Buspirone.
CimetidineThe metabolism of Buspirone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Buspirone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Buspirone.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Buspirone.
CitalopramThe risk or severity of adverse effects can be increased when Buspirone is combined with Citalopram.
CitalopramThe metabolism of Buspirone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Buspirone can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Buspirone.
ClemastineThe metabolism of Buspirone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Buspirone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Buspirone is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Buspirone.
ClobazamThe metabolism of Buspirone can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Buspirone.
ClomipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Clomipramine.
ClomipramineThe metabolism of Buspirone can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Buspirone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Buspirone.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Buspirone.
ClorazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.
ClotrimazoleThe metabolism of Buspirone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Clozapine.
ClozapineThe metabolism of Buspirone can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Buspirone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Buspirone.
CocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Buspirone.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Buspirone.
ConivaptanThe serum concentration of Buspirone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buspirone.
CrizotinibThe metabolism of Buspirone can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Buspirone.
CyamemazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Buspirone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Buspirone.
CyproheptadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Buspirone.
DabrafenibThe serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Buspirone.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Buspirone.
DantroleneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Buspirone.
DapiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.
DarifenacinThe metabolism of Buspirone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Buspirone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Buspirone.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Buspirone.
Decanoic AcidThe metabolism of Buspirone can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Buspirone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Buspirone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane.
DesipramineThe metabolism of Buspirone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Detomidine.
DexamethasoneThe serum concentration of Buspirone can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Buspirone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine.
DextromethorphanThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Buspirone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Buspirone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buspirone.
DifenoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Buspirone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Buspirone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Buspirone can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Buspirone.
DiltiazemThe metabolism of Buspirone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Buspirone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Buspirone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Buspirone.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Buspirone.
DolasetronDolasetron may increase the serotonergic activities of Buspirone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Buspirone.
DoramectinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Buspirone.
DoxycyclineThe metabolism of Buspirone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
DoxylamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Buspirone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
DronedaroneThe metabolism of Buspirone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Drotebanol.
DuloxetineThe metabolism of Buspirone can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Buspirone is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Buspirone is combined with ECGONINE METHYL ESTER.
EconazoleThe metabolism of Buspirone can be decreased when combined with Econazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Buspirone.
EfavirenzThe serum concentration of Buspirone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Buspirone is combined with Efavirenz.
EfinaconazoleThe metabolism of Buspirone can be decreased when combined with Efinaconazole.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Buspirone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Buspirone.
EliglustatThe metabolism of Buspirone can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Buspirone.
EntacaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone.
EnzalutamideThe serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Buspirone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Buspirone.
ErythromycinThe metabolism of Buspirone can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Buspirone.
EscitalopramThe risk or severity of adverse effects can be increased when Buspirone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Buspirone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Buspirone.
EstriolThe serum concentration of Estriol can be increased when it is combined with Buspirone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Buspirone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buspirone.
EthanolBuspirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Buspirone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buspirone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buspirone.
EthosuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Buspirone.
EtoperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Buspirone.
EtorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etorphine.
EtravirineThe serum concentration of Buspirone can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Buspirone.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Buspirone.
EzogabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Buspirone.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Buspirone.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Buspirone.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Buspirone.
FlibanserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.
FluconazoleThe metabolism of Buspirone can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Buspirone can be decreased when combined with Flucytosine.
FludiazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluoxetine.
FluoxetineThe metabolism of Buspirone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Buspirone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluvoxamine.
FluvoxamineThe metabolism of Buspirone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Buspirone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Buspirone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Buspirone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Frovatriptan.
FurazolidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.
Fusidic AcidThe serum concentration of Buspirone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Buspirone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Buspirone is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Buspirone.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Buspirone.
GlutethimideThe risk or severity of adverse effects can be increased when Buspirone is combined with Glutethimide.
GlyphosateThe metabolism of Buspirone can be decreased when combined with Glyphosate.
GranisetronGranisetron may increase the serotonergic activities of Buspirone.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Buspirone.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Buspirone.
GriseofulvinThe metabolism of Buspirone can be decreased when combined with Griseofulvin.
GuanfacineThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Haloperidol.
HaloperidolThe metabolism of Buspirone can be decreased when combined with Haloperidol.
HaloproginThe metabolism of Buspirone can be decreased when combined with Haloprogin.
HalothaneThe risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Buspirone is combined with Heroin.
HexetidineThe metabolism of Buspirone can be decreased when combined with Hexetidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Hexobarbital.
HydracarbazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Buspirone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
HydroxyzineThe risk or severity of adverse effects can be increased when Buspirone is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Buspirone.
IdelalisibThe serum concentration of Buspirone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.
ImatinibThe metabolism of Buspirone can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Buspirone.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Buspirone.
ImipramineThe metabolism of Buspirone can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Buspirone.
IndalpineThe risk or severity of adverse effects can be increased when Buspirone is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Buspirone.
IndinavirThe metabolism of Buspirone can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Buspirone.
Ioflupane I-123Buspirone may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproniazid.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Buspirone.
IsavuconazoniumThe metabolism of Buspirone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Buspirone is combined with Isocarboxazid.
IsoconazoleThe metabolism of Buspirone can be decreased when combined with Isoconazole.
IsofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Isoflurane.
IsoniazidThe metabolism of Buspirone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Buspirone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Buspirone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Buspirone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Buspirone.
KetamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Buspirone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Buspirone.
KetobemidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Buspirone.
KetoconazoleThe metabolism of Buspirone can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Buspirone.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Buspirone.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Buspirone.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Buspirone.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Buspirone.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Buspirone.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Buspirone.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Buspirone.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Buspirone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Buspirone is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Buspirone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Buspirone.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Buspirone.
LinezolidThe risk or severity of adverse effects can be increased when Buspirone is combined with Linezolid.
LithiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Buspirone.
LopinavirThe metabolism of Buspirone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Buspirone.
LorcaserinThe metabolism of Buspirone can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Buspirone.
LovastatinThe metabolism of Buspirone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Buspirone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Buspirone can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Buspirone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Buspirone is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Buspirone.
MaprotilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Buspirone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.
MesoridazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.
MethadoneThe metabolism of Buspirone can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Buspirone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Buspirone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.
Methylene blueThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Buspirone.
MetoclopramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Buspirone.
MetoprololThe metabolism of Buspirone can be decreased when combined with Metoprolol.
MetyrosineBuspirone may increase the sedative activities of Metyrosine.
MevastatinThe metabolism of Buspirone can be decreased when combined with Mevastatin.
MicafunginThe metabolism of Buspirone can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Buspirone can be decreased when combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Buspirone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Buspirone.
MifepristoneThe metabolism of Buspirone can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Buspirone is combined with Milnacipran.
MiltefosineThe metabolism of Buspirone can be decreased when combined with Miltefosine.
MinaprineThe risk or severity of adverse effects can be increased when Buspirone is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Buspirone.
MirabegronThe metabolism of Buspirone can be decreased when combined with Mirabegron.
MirtazapineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Buspirone.
MitotaneThe serum concentration of Buspirone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Buspirone.
MoclobemideThe risk or severity of adverse effects can be increased when Buspirone is combined with Moclobemide.
ModafinilThe serum concentration of Buspirone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Molindone.
MonensinThe metabolism of Buspirone can be decreased when combined with Monensin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Buspirone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Buspirone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buspirone.
MyxothiazolThe metabolism of Buspirone can be decreased when combined with Myxothiazol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
NabiloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Buspirone.
NafcillinThe serum concentration of Buspirone can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Buspirone can be decreased when combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Buspirone.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Buspirone.
NaratriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Naratriptan.
NatamycinThe metabolism of Buspirone can be decreased when combined with Natamycin.
NefazodoneThe metabolism of Buspirone can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Nefazodone.
NelfinavirThe metabolism of Buspirone can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Buspirone.
NetupitantThe serum concentration of Buspirone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Buspirone can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Buspirone is combined with Nialamide.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Buspirone.
NicardipineThe metabolism of Buspirone can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Buspirone.
NilotinibThe metabolism of Buspirone can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Buspirone.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Buspirone.
NitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrous oxide.
NitroxolineThe metabolism of Buspirone can be decreased when combined with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Buspirone.
NormethadoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nortriptyline.
NystatinThe metabolism of Buspirone can be decreased when combined with Nystatin.
OctamoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Olanzapine.
OlaparibThe metabolism of Buspirone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Buspirone.
OndansetronThe risk or severity of adverse effects can be increased when Buspirone is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Buspirone.
OpiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Opium.
OrphenadrineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Buspirone.
OsanetantThe risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.
OsimertinibThe serum concentration of Buspirone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxazepam.
OxiconazoleThe metabolism of Buspirone can be decreased when combined with Oxiconazole.
OxprenololThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxymorphone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Buspirone.
pafuramidineThe metabolism of Buspirone can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Buspirone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Buspirone.
PanobinostatThe metabolism of Buspirone can be decreased when combined with Panobinostat.
ParaldehydeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Buspirone.
PargylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Buspirone is combined with Paroxetine.
ParoxetineThe metabolism of Buspirone can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.
Peginterferon alfa-2bThe serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Buspirone can be decreased when combined with Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Buspirone.
PerampanelThe risk or severity of adverse effects can be increased when Buspirone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Buspirone.
PhenelzineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pheniprazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Buspirone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Buspirone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoxypropazine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Buspirone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Buspirone.
PimozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipotiazine.
PirlindoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Buspirone.
PivhydrazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Buspirone is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Buspirone.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Buspirone.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Buspirone.
PosaconazoleThe metabolism of Buspirone can be decreased when combined with Posaconazole.
PramipexoleBuspirone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Buspirone.
PrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Buspirone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Buspirone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Buspirone.
PrilocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Buspirone.
PromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Promazine.
PromazineThe metabolism of Buspirone can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Buspirone.
ProtriptylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Buspirone.
PSD502The risk or severity of adverse effects can be increased when Buspirone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Quetiapine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Buspirone.
QuinidineThe metabolism of Buspirone can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Buspirone.
QuinineThe metabolism of Buspirone can be decreased when combined with Quinine.
RadicicolThe metabolism of Buspirone can be decreased when combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Buspirone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Buspirone.
RanolazineThe metabolism of Buspirone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Buspirone is combined with Reserpine.
RifabutinThe metabolism of Buspirone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Buspirone can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Buspirone.
RifapentineThe metabolism of Buspirone can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Buspirone.
RisperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone.
RitonavirThe metabolism of Buspirone can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Buspirone.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Buspirone.
RizatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Rizatriptan.
RolapitantThe metabolism of Buspirone can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Buspirone.
RomifidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Romifidine.
RopiniroleBuspirone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Buspirone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone.
RotigotineBuspirone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Buspirone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Buspirone is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Safrazine.
Salicylhydroxamic AcidThe metabolism of Buspirone can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Buspirone can be decreased when combined with Salicylic acid.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Buspirone.
SaquinavirThe metabolism of Buspirone can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Buspirone.
ScopolamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.
SelegilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Buspirone.
SertaconazoleThe metabolism of Buspirone can be decreased when combined with Sertaconazole.
SertindoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertraline.
SertralineThe metabolism of Buspirone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.
SildenafilThe metabolism of Buspirone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Buspirone.
SiltuximabThe serum concentration of Buspirone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Buspirone can be increased when it is combined with Simeprevir.
SinefunginThe metabolism of Buspirone can be decreased when combined with Sinefungin.
SirolimusThe metabolism of Buspirone can be decreased when combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Buspirone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Buspirone is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Buspirone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Buspirone.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Buspirone.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Buspirone.
St. John's WortThe serum concentration of Buspirone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Buspirone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.
SulconazoleThe metabolism of Buspirone can be decreased when combined with Sulconazole.
SulfisoxazoleThe metabolism of Buspirone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Sumatriptan.
SuvorexantThe risk or severity of adverse effects can be increased when Buspirone is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Buspirone.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Buspirone.
TapentadolThe risk or severity of adverse effects can be increased when Buspirone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Buspirone.
TavaboroleThe metabolism of Buspirone can be decreased when combined with Tavaborole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Buspirone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Buspirone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Buspirone is combined with Tedizolid Phosphate.
TelaprevirThe metabolism of Buspirone can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Buspirone.
TelithromycinThe metabolism of Buspirone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Buspirone.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Buspirone.
TerbinafineThe metabolism of Buspirone can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Buspirone can be decreased when combined with Terconazole.
TetrabenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrodotoxin.
ThalidomideBuspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Buspirone.
ThiamylalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.
ThymolThe metabolism of Buspirone can be decreased when combined with Thymol.
TiagabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Buspirone.
TiclopidineThe metabolism of Buspirone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Buspirone.
TioconazoleThe metabolism of Buspirone can be decreased when combined with Tioconazole.
TipranavirThe metabolism of Buspirone can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.
TocilizumabThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.
TolnaftateThe metabolism of Buspirone can be decreased when combined with Tolnaftate.
ToloxatoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Toloxatone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Buspirone.
TopiramateThe risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Buspirone.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Buspirone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.
TranylcypromineThe metabolism of Buspirone can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Buspirone.
TrazodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.
TrimetrexateThe metabolism of Buspirone can be decreased when combined with Trimetrexate.
TrimipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Buspirone.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Buspirone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Buspirone.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Buspirone.
VenlafaxineThe metabolism of Buspirone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Buspirone.
VerapamilThe metabolism of Buspirone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Buspirone.
VigabatrinThe risk or severity of adverse effects can be increased when Buspirone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Buspirone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Buspirone.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Buspirone.
VoriconazoleThe metabolism of Buspirone can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Buspirone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Xylazine.
YohimbineThe therapeutic efficacy of Buspirone can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Buspirone.
ZimelidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziprasidone.
ZiprasidoneThe metabolism of Buspirone can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Buspirone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Buspirone.
ZonisamideThe risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Buspirone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.
Food Interactions
  • Always take at the same time with respect to meals.
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. de Boer SF, Lesourd M, Mocaer E, Koolhaas JM: Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J Pharmacol Exp Ther. 1999 Mar;288(3):1125-33. [PubMed:10027850 ]
  2. Rehman J, Kaynan A, Christ G, Valcic M, Maayani S, Melman A: Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor. Brain Res. 1999 Mar 13;821(2):414-25. [PubMed:10064829 ]
  3. Liang KC: Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors. Eur J Neurosci. 1999 May;11(5):1491-500. [PubMed:10215901 ]
  4. Becker C, Hamon M, Benoliel JJ: Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology. 1999 Apr;38(4):525-32. [PubMed:10221756 ]
  5. Dupuis DS, Tardif S, Wurch T, Colpaert FC, Pauwels PJ: Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein. Neuropharmacology. 1999 Jul;38(7):1035-41. [PubMed:10428422 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Osei-Owusu P, Scrogin KE: Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage. J Pharmacol Exp Ther. 2004 Jun;309(3):1132-40. Epub 2004 Feb 9. [PubMed:14769835 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H: Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003 Jun;75(1):77-82. [PubMed:12781354 ]
  2. Boido A, Boido CC, Sparatore F: Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes. Farmaco. 2001 Apr;56(4):263-75. [PubMed:11421254 ]
  3. Nader MA, Hannemann M: Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons. Behav Pharmacol. 1993 Jun;4(3):263-268. [PubMed:11224194 ]
  4. Pache DM, Fernandez-Perez S, Sewell RD: Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task. Eur J Pharmacol. 2003 Sep 23;477(3):205-11. [PubMed:14522358 ]
  5. Fernandez-Perez S, Pache DM, Sewell RD: Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur J Pharmacol. 2005 Oct 17;522(1-3):78-83. Epub 2005 Oct 7. [PubMed:16214127 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23